Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition-Reference-Cited by-同舟云学术

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Published:2022-01 Issue:1 Volume:24 Page:1-11
ISSN:1476-5586
Container-title:Neoplasia
language:en
Short-container-title:Neoplasia

Author:

Bennett Melissa K.,Li Manjun^ORCID,Tea Melinda N.^ORCID,Pitman Melissa R.,Toubia John^ORCID,Wang Paul P.-S.^ORCID,Anderson Dovile,Creek Darren J.^ORCID,Orlowski Robert Z.,Gliddon Briony L.,Powell Jason A.,Wallington-Beddoe Craig T.^ORCID,Pitson Stuart M.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research

Reference50 articles.

1. Multiple myeloma: diagnosis and treatment;Rajkumar;Mayo Clinic proceedings,2016

2. Clinical use of proteasome inhibitors in the treatment of multiple myeloma;Merin;Pharmaceuticals,2014

3. The proteasome and proteasome inhibitors in multiple myeloma;Gandolfi;Cancer Metastasis Rev,2017

4. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma;Kubiczkova;Journal of cellular and molecular medicine,2014

5. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma;Vincenz;Molecular cancer therapeutics,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The sphingosine kinase 2 inhibitors ABC294640 and K145 elevate (dihydro)sphingosine 1-phosphate levels in various cells;Journal of Lipid Research;2024-08

2. An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma;British Journal of Haematology;2023-12-05

3. Advances in research on potential inhibitors of multiple myeloma;European Journal of Medicinal Chemistry;2023-12

4. Lipid metabolic vulnerabilities of multiple myeloma;Clinical and Experimental Medicine;2023-08-28

5. Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance;Cancers;2023-03-09